Journal Of Leukemia
ISSN: 2329-6917
OPEN ACCESS Freely available online
Editorial

A Brief Note on Leukemia

Stella Brambilla*

Department of Medicine, Surgery and Neuroscience, University of Naples, Corso Umberto, Napoli, NA, Italy

DESCRIPTION

Acute Lymphoblastic Leukaemia (ALL) is a malignancy of the lymphoid line of blood cells characterized by the proliferation of immature lymphocytes in enormous numbers. Tiredness, pale complexion, fever, easy bleeding or bruising, swollen lymph nodes, and bone discomfort are all possible symptoms. ALL advances quickly as an acute leukaemia and is usually lethal within weeks or months if left untreated. In the vast majority of instances, the reason is unknown. Down syndrome, Li-Fraumeni syndrome, and neurofibromatosis types 1 are all genetic risk factors.

Significant radiation exposure or past treatments are examples of environmental risk factors. There is no conclusive evidence for electromagnetic fields or pesticides. Some believe a cause might be an aberrant immunological response to a common virus. Multiple genetic changes are involved in the underlying process, which leads in fast cell proliferation. Excessive immature lymphocytes in the bone marrow obstruct the generation of new red, white, and platelet cells.

Chemotherapy is commonly used to treat ALL in the early stages, with the goal of achieving remission. This is usually followed by further chemotherapy over a period of years. Because systemic chemotherapy has limited penetration into the central nervous system, and the central nervous system is a common location for recurrence of acute lymphoblastic leukaemia, treatment generally includes intrathecal chemotherapy. If the cancer has gone to the brain, treatment may involve radiation therapy. If the condition recurs after regular treatment, stem cell transplantation may be utilized. Additional therapies are being utilized and explored, such as chimeric antigen receptor T cell immunotherapy. The lymphoblast is the malignant cell in ALL. Normal lymphoblasts grow into infection fighting B-cells or T-cells, which are also known as lymphocytes. ALL is caused by numerous mutations in genes that impact blood cell formation and proliferation in a single lymphoblast. This process begins at conception in ALL children, with the inheritance of some of these genes. As a result of these genes, there's a higher chance that more mutations will arise in growing lymphoid cells. Down syndrome and other genetic abnormalities have the same impact.

To help develop enough genetic changes to induce illness, environmental risk factors are also required. Childhood ALL in twins, where only 10-15 per cent of both genetically identical twins have ALL, provides evidence for the impact of the environment. Different environmental exposures explain why one twin gets ALL while the other does not, despite the fact that they have the identical genes.

A detailed medical history, physical examination, full blood count, and blood smears are used to diagnose ALL. While many of the symptoms of ALL are similar to those of other diseases, persistent or unexplained symptoms raise the possibility of malignancy. Because many aspects of the medical history and examination are not unique to ALL, further testing is frequently required.

Because they indicate a fast development of lymphoid cells in the marrow, a significant number of white blood cells and lymphoblasts in the circulating blood might be suspicious for ALL. While white blood cell counts might vary widely at first presentation, circulating lymphoblast cells can usually be identified on peripheral blood smears. A bone marrow biopsy confirms the diagnosis of ALL, with leukemic lymphoblasts accounting for more than 20% of all cells.

Correspondence to: Dr. Stella Brambilla, Department Surgery and Neuroscience, University of Naples, Corso Umberto ,Napoli , NA, Italy; E-mail: brambilla.stella@isaitaly.com

Received: November 01, 2021; **Accepted**: November 15, 2021; **Published**: November 22, 2021

Citation: Brambilla S (2021) A Brief Note on Leukemia. J Leuk. 9:e138.